Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND AND AIM: Hepatectomy remains the standard treatment for Barcelona Clinic Liver Cancer (BCLC) stage 0/A hepatocellular carcinoma (HCC). However, debates persist regarding the optimal surgical approach - robot-assisted (RALR), laparoscopic (LLR), or open liver resection (OLR) - due to differences in perioperative outcomes, recurrence, and cost-effectiveness. While minimally invasive techniques offer potential advantages, such as reduced morbidity and faster recovery, their comprehensive impact remains unclear. This study evaluates and compares the intraoperative, postoperative, and economic outcomes of these three approaches in a multicenter cohort of BCLC 0/A HCC patients. METHOD: Propensity score matching (PSM) was used to balance baseline characteristics across RALR, LLR, and OLR groups (714 patients each). Intraoperative and postoperative outcomes, as well as recurrence-free survival and overall survival, were assessed. Cost-effectiveness was assessed based on quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). RESULT: This nationwide retrospective study analyzed 2882 BCLC 0/A HCC patients from 27 centers. After PSM, 2142 patients were analyzed (714 in each group). Operative time was longer in RALR (225 min) and LLR (225 min) compared to OLR (170 min, P < 0.001). Postoperative complication rates were lower in RALR (12.5%) and LLR (13.4%) than in OLR (17.1%), with fewer severe complications. The OLR group had a higher proportion of advanced-stage recurrences (BCLC B/C/D: 70.3%) versus RALR (37.9%) and LLR (35.9%) ( P < 0.001). RALR achieved the highest 5-year QALYs (1.143) among the three groups, while LLR demonstrated superior cost-effectiveness with an ICER of -$24 379/QALY compared to OLR. CONCLUSION: RALR and LLR demonstrated lower incidence and severity of complications, less advanced-stage recurrence, and higher cost-effectiveness compared to OLR. These findings support the broader adoption of minimally invasive techniques to improve long-term outcomes and quality of life (QoL). Despite RALR's higher initial costs, it remains a highly cost-effective option, offering superior QoL and long-term economic benefits.
Source: International Journal of Surgery
Authors: Feng Xia, Xulin Liu, Jing Yan, Zhancheng Qiu, Qiao Zhang, Zhenheng Wu, Zhiyuan Huang, Renjie Wei, Li Lin, Liping Liu, Shuangqin Han, Yulin Yuan, Huaxuan Yin, Guobing Xia, Yunyan Wan, Shuo Xiao, Jian Li, Guoxiang Zhou, Xiafei Xia, Huapeng Sun, Shuai Wang, Jun Zheng, Hengyi Gao, Jiang Zheng, Li Ren, Mo Ali, Junquan Fu, Lin Ye, Shun Ruan, Xiaoping Chen, Qi Cheng, Bixiang Zhang, Peng Zhu
Institutions: Tongji Hospital, Huazhong University of Science and Technology, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Guangdong Medical College, Zhongshan People's Hospital, Union Hospital, General Hospital of Central Theater Command, Zhongnan Hospital of Wuhan University, Wuhan Union Hospital, ShenZhen People’s Hospital, Tianjin First Center Hospital, Tianjin Medical University, Wuhan University of Science and Technology, First People's Hospital of Foshan, Hubei Polytechnic University, Huangshi Central Hospital, Taihe Hospital, Guangdong Provincial People's Hospital, Southern Medical University, Renmin Hospital of Wuhan University, Qingdao University, Qingdao Women and Children's Hospital, Kunming Medical University, First Affiliated Hospital of Kunming Medical University, Hubei University of Arts and Science, Xiangyang Central Hospital, Jingzhou Central Hospital, Shenzhen Bao'an District People's Hospital, Qinghai University, Qinghai University Affiliated Hospital, Shaoyang University, Guilin Medical University
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,450
OpenAlex ID: W4416617014